nodes	percent_of_prediction	percent_of_DWPC	metapath
Rabeprazole—ABCG2—Topotecan—cervical cancer	0.694	0.822	CbGbCtD
Rabeprazole—CYP3A4—Topotecan—cervical cancer	0.15	0.178	CbGbCtD
Rabeprazole—Lung neoplasm malignant—Topotecan—cervical cancer	0.016	0.129	CcSEcCtD
Rabeprazole—Pelvic pain—Topotecan—cervical cancer	0.00528	0.0425	CcSEcCtD
Rabeprazole—Neuralgia—Topotecan—cervical cancer	0.00462	0.0372	CcSEcCtD
Rabeprazole—Lung disorder—Topotecan—cervical cancer	0.00454	0.0365	CcSEcCtD
Rabeprazole—Interstitial lung disease—Topotecan—cervical cancer	0.00454	0.0365	CcSEcCtD
Rabeprazole—ATP4A—epithelium—cervical cancer	0.00388	0.124	CbGeAlD
Rabeprazole—ATP4A—renal system—cervical cancer	0.0036	0.115	CbGeAlD
Rabeprazole—Dysmenorrhoea—Topotecan—cervical cancer	0.00353	0.0284	CcSEcCtD
Rabeprazole—Bone pain—Topotecan—cervical cancer	0.00335	0.027	CcSEcCtD
Rabeprazole—Respiratory failure—Topotecan—cervical cancer	0.00327	0.0263	CcSEcCtD
Rabeprazole—Pulmonary embolism—Topotecan—cervical cancer	0.00321	0.0258	CcSEcCtD
Rabeprazole—Colitis—Topotecan—cervical cancer	0.00308	0.0248	CcSEcCtD
Rabeprazole—Neuropathy—Topotecan—cervical cancer	0.00301	0.0243	CcSEcCtD
Rabeprazole—Neoplasm—Topotecan—cervical cancer	0.0029	0.0234	CcSEcCtD
Rabeprazole—ATP4A—female reproductive system—cervical cancer	0.00288	0.092	CbGeAlD
Rabeprazole—Ear pain—Topotecan—cervical cancer	0.00273	0.022	CcSEcCtD
Rabeprazole—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00206	0.0165	CcSEcCtD
Rabeprazole—Pancytopenia—Topotecan—cervical cancer	0.00191	0.0154	CcSEcCtD
Rabeprazole—Neutropenia—Topotecan—cervical cancer	0.00188	0.0152	CcSEcCtD
Rabeprazole—Weight increased—Topotecan—cervical cancer	0.00183	0.0148	CcSEcCtD
Rabeprazole—Pneumonia—Topotecan—cervical cancer	0.00181	0.0145	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Topotecan—cervical cancer	0.00176	0.0142	CcSEcCtD
Rabeprazole—Stomatitis—Topotecan—cervical cancer	0.00175	0.0141	CcSEcCtD
Rabeprazole—Sweating—Topotecan—cervical cancer	0.00172	0.0139	CcSEcCtD
Rabeprazole—Epistaxis—Topotecan—cervical cancer	0.00169	0.0136	CcSEcCtD
Rabeprazole—Rhinitis—Topotecan—cervical cancer	0.00162	0.013	CcSEcCtD
Rabeprazole—Pharyngitis—Topotecan—cervical cancer	0.0016	0.0129	CcSEcCtD
Rabeprazole—Angiopathy—Topotecan—cervical cancer	0.00146	0.0118	CcSEcCtD
Rabeprazole—Chills—Topotecan—cervical cancer	0.00145	0.0116	CcSEcCtD
Rabeprazole—Alopecia—Topotecan—cervical cancer	0.00142	0.0115	CcSEcCtD
Rabeprazole—Malnutrition—Topotecan—cervical cancer	0.0014	0.0113	CcSEcCtD
Rabeprazole—Back pain—Topotecan—cervical cancer	0.00136	0.0109	CcSEcCtD
Rabeprazole—Muscle spasms—Topotecan—cervical cancer	0.00135	0.0109	CcSEcCtD
Rabeprazole—Ill-defined disorder—Topotecan—cervical cancer	0.0013	0.0105	CcSEcCtD
Rabeprazole—Anaemia—Topotecan—cervical cancer	0.0013	0.0104	CcSEcCtD
Rabeprazole—Angioedema—Topotecan—cervical cancer	0.00128	0.0103	CcSEcCtD
Rabeprazole—Malaise—Topotecan—cervical cancer	0.00127	0.0102	CcSEcCtD
Rabeprazole—Leukopenia—Topotecan—cervical cancer	0.00126	0.0101	CcSEcCtD
Rabeprazole—Cough—Topotecan—cervical cancer	0.00122	0.00986	CcSEcCtD
Rabeprazole—Myalgia—Topotecan—cervical cancer	0.0012	0.00962	CcSEcCtD
Rabeprazole—Arthralgia—Topotecan—cervical cancer	0.0012	0.00962	CcSEcCtD
Rabeprazole—Chest pain—Topotecan—cervical cancer	0.0012	0.00962	CcSEcCtD
Rabeprazole—Discomfort—Topotecan—cervical cancer	0.00118	0.0095	CcSEcCtD
Rabeprazole—Anaphylactic shock—Topotecan—cervical cancer	0.00115	0.00922	CcSEcCtD
Rabeprazole—ABCG2—uterine cervix—cervical cancer	0.00114	0.0364	CbGeAlD
Rabeprazole—Thrombocytopenia—Topotecan—cervical cancer	0.00112	0.00903	CcSEcCtD
Rabeprazole—Hyperhidrosis—Topotecan—cervical cancer	0.00111	0.00891	CcSEcCtD
Rabeprazole—Anorexia—Topotecan—cervical cancer	0.00109	0.00879	CcSEcCtD
Rabeprazole—CYP1A1—epithelium—cervical cancer	0.00109	0.0349	CbGeAlD
Rabeprazole—ABCG2—decidua—cervical cancer	0.00109	0.0347	CbGeAlD
Rabeprazole—CYP1A1—uterine cervix—cervical cancer	0.00108	0.0346	CbGeAlD
Rabeprazole—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00104	0.0084	CcSEcCtD
Rabeprazole—ABCG2—endometrium—cervical cancer	0.00103	0.0329	CbGeAlD
Rabeprazole—Paraesthesia—Topotecan—cervical cancer	0.00103	0.00828	CcSEcCtD
Rabeprazole—CYP1A2—renal system—cervical cancer	0.00103	0.0328	CbGeAlD
Rabeprazole—Dyspnoea—Topotecan—cervical cancer	0.00102	0.00822	CcSEcCtD
Rabeprazole—CYP1A1—renal system—cervical cancer	0.00101	0.0323	CbGeAlD
Rabeprazole—Dyspepsia—Topotecan—cervical cancer	0.00101	0.00811	CcSEcCtD
Rabeprazole—ABCG2—mammalian vulva—cervical cancer	0.000997	0.0319	CbGeAlD
Rabeprazole—Decreased appetite—Topotecan—cervical cancer	0.000996	0.00801	CcSEcCtD
Rabeprazole—Pain—Topotecan—cervical cancer	0.00098	0.00788	CcSEcCtD
Rabeprazole—Constipation—Topotecan—cervical cancer	0.00098	0.00788	CcSEcCtD
Rabeprazole—ABCG2—uterus—cervical cancer	0.000949	0.0303	CbGeAlD
Rabeprazole—CYP1A1—mammalian vulva—cervical cancer	0.000946	0.0302	CbGeAlD
Rabeprazole—Feeling abnormal—Topotecan—cervical cancer	0.000944	0.0076	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Topotecan—cervical cancer	0.000937	0.00754	CcSEcCtD
Rabeprazole—Urticaria—Topotecan—cervical cancer	0.00091	0.00732	CcSEcCtD
Rabeprazole—CYP2C19—vagina—cervical cancer	0.00091	0.0291	CbGeAlD
Rabeprazole—Body temperature increased—Topotecan—cervical cancer	0.000906	0.00729	CcSEcCtD
Rabeprazole—Abdominal pain—Topotecan—cervical cancer	0.000906	0.00729	CcSEcCtD
Rabeprazole—CYP1A1—uterus—cervical cancer	0.000901	0.0288	CbGeAlD
Rabeprazole—Hypersensitivity—Topotecan—cervical cancer	0.000844	0.00679	CcSEcCtD
Rabeprazole—Asthenia—Topotecan—cervical cancer	0.000822	0.00661	CcSEcCtD
Rabeprazole—Pruritus—Topotecan—cervical cancer	0.000811	0.00652	CcSEcCtD
Rabeprazole—CYP1A1—female reproductive system—cervical cancer	0.00081	0.0259	CbGeAlD
Rabeprazole—Diarrhoea—Topotecan—cervical cancer	0.000784	0.00631	CcSEcCtD
Rabeprazole—CYP2C9—female reproductive system—cervical cancer	0.00078	0.0249	CbGeAlD
Rabeprazole—ABCG2—female gonad—cervical cancer	0.000777	0.0248	CbGeAlD
Rabeprazole—ABCG2—vagina—cervical cancer	0.000772	0.0247	CbGeAlD
Rabeprazole—Dizziness—Topotecan—cervical cancer	0.000758	0.0061	CcSEcCtD
Rabeprazole—CYP3A4—renal system—cervical cancer	0.000742	0.0237	CbGeAlD
Rabeprazole—CYP1A1—female gonad—cervical cancer	0.000737	0.0236	CbGeAlD
Rabeprazole—CYP1A1—vagina—cervical cancer	0.000733	0.0234	CbGeAlD
Rabeprazole—CYP2D6—renal system—cervical cancer	0.000731	0.0233	CbGeAlD
Rabeprazole—Vomiting—Topotecan—cervical cancer	0.000728	0.00586	CcSEcCtD
Rabeprazole—Rash—Topotecan—cervical cancer	0.000722	0.00581	CcSEcCtD
Rabeprazole—Dermatitis—Topotecan—cervical cancer	0.000722	0.00581	CcSEcCtD
Rabeprazole—Headache—Topotecan—cervical cancer	0.000718	0.00578	CcSEcCtD
Rabeprazole—Nausea—Topotecan—cervical cancer	0.00068	0.00548	CcSEcCtD
Rabeprazole—CYP3A4—female reproductive system—cervical cancer	0.000595	0.019	CbGeAlD
Rabeprazole—CYP2D6—female reproductive system—cervical cancer	0.000585	0.0187	CbGeAlD
Rabeprazole—CYP2D6—female gonad—cervical cancer	0.000532	0.017	CbGeAlD
Rabeprazole—ABCG2—lymph node—cervical cancer	0.000499	0.016	CbGeAlD
Rabeprazole—CYP1A1—lymph node—cervical cancer	0.000474	0.0151	CbGeAlD
